sales@fnfresearch.comTel: +86 21 80360450 | USA: +1-347-989-3985

Search Market Research Report

Home / Healthcare / Hemoglobinopathies

Hemoglobinopathies Market by Indication (Sickle cell disease, Alpha Thalassemia, Beta Thalassemia and Others), Therapy (Blood Transfusion, Iron Chelation Therapy, Bone Marrow Transplant and Others), Diagnosis (Blood testing, Genetic testing, Pre-implantation Genetic Diagnosis (PGD) and Other), and end user (Hospitals, Diagnostic laboratories, Clinics and Other End-user): Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 2020–2026

  • Publish On: May-2020
  • Total Pages: 185
  • Report Code: FAF-1033
  • Base Year: 2019
  • Format:

Industry Insights

This specialized and expertise oriented industry research report scrutinizes the technical and commercial business outlook of the Hemoglobinopathies industry. The report analyzes and declares the historical and current trends analysis of the Hemoglobinopathies industry and subsequently recommends the projected trends anticipated to be observed in the Hemoglobinopathies market during the upcoming years.

The Hemoglobinopathies market report analyzes and notifies the industry statistics at the global as well as regional and country levels in order to acquire a thorough perspective of the entire Hemoglobinopathies market. The historical and past insights are provided for FY 2016 to FY 2019 whereas projected trends are delivered for FY 2020 to FY 2026. The quantitative and numerical data is represented in terms of value (USD Million) from FY 2016 – 2026.

The quantitative data is further underlined and reinforced by comprehensive qualitative data which comprises various across-the-board market dynamics. The rationales which directly or indirectly impact the Hemoglobinopathies industry are exemplified through parameters such as growth drivers, restraints, challenges, and opportunities among other impacting factors.

Throughout our research report, we have encompassed all the proven models and tools of industry analysis and extensively illustrated all the key business strategies and business models adopted in the Hemoglobinopathies industry. The report provides an all-inclusive and detailed competitive landscape prevalent in the Hemoglobinopathies market.

The report utilizes established industry analysis tools and models such as Porter’s Five Forces framework to analyze and recognize critical business strategies adopted by various stakeholders involved in the entire value chain of the Hemoglobinopathies industry. The Hemoglobinopathies market report additionally employs SWOT analysis and PESTLE analysis models for further in-depth analysis.

The report study further includes an in-depth analysis of industry players' market shares and provides an overview of leading players' market position in the Hemoglobinopathies sector. Key strategic developments in the Hemoglobinopathies market competitive landscape such as acquisitions & mergers, inaugurations of different products and services, partnerships & joint ventures, MoU agreements, VC & funding activities, R&D activities, and geographic expansion among other noteworthy activities by key players of the Hemoglobinopathies market are appropriately highlighted in the report.

The Hemoglobinopathies market research report delivers an acute valuation and taxonomy of the Hemoglobinopathies industry by practically splitting the market on the basis of different types, category and regions. Through the analysis of the historical and projected trends, all the segments and sub-segments were evaluated through the bottom-up approach, and different market sizes have been projected for FY 2020 to FY 2026. The regional segmentation of the Hemoglobinopathies industry includes the complete classification of all the major continents including North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Further, country-wise data for the Hemoglobinopathies industry is provided for the leading economies of the world.

Hemoglobinopathies are caused by defects in the genes and by anemia. Default hemoglobin formation is observed in three conditions, such as hemoglobin molecule structural defects, reduced production of one of the two hemoglobin molecule subunits, and abnormal interactions of otherwise safe subunits. There can be serious or mild illnesses. Genetic diagnosis, genetic and blood testing, electrophoresis of alkaline and acid gel, hemoglobin electrophoresis, genetic prenatal testing, and chromatography exchange of ions HbA2 are the most common tools/tests for diagnosis of hemoglobinopathy and thalassemia.

The Hemoglobinopathies market is segmented into indication, therapy, diagnosis, end-user, and region segment. The indication segment is segmented into sickle cell disease, alpha-thalassemia, beta-thalassemia, and others. The therapy segment is divided into iron chelation therapy, blood transfusion, bone marrow transplant, and others. The Diagnosis segment is bifurcated into blood testing, genetic testing, pre-implantation genetic diagnosis (PGD), and Others. The end-user segment is segmented into hospitals, diagnostic laboratories, clinics, and other end-user.

Some of the essential players operating in the Alnylam Pharmaceuticals, bluebird bio Inc., Celgene Corporation, Emmaus Life Sciences Inc., Gamida Cell, Global Blood Therapeutics, Prolong Pharmaceuticals, Sangamo, Therapeutics Inc., Sanofi amongst others.

The taxonomy of the Hemoglobinopathies industry by its scope and segmentation is as follows:

Global Hemoglobinopathies Market: Indication Segment Analysis

  • Sickle cell disease
  • Alpha Thalassemia
  • Beta Thalassemia
  • Others

Global Hemoglobinopathies Market: Therapy Segment Analysis

  • Blood Transfusion
  • Iron Chelation Therapy
  • Bone Marrow Transplant
  • Others

Global Hemoglobinopathies Market: Diagnosis Segment Analysis

  • Blood testing
  • Genetic testing
  • Pre-implantation Genetic Diagnosis (PGD)
  • Other

Global Hemoglobinopathies Market: End-user Segment Analysis

  • Hospitals
  • Diagnostic laboratories
  • Clinics
  • Other End-use

Global Hemoglobinopathies Market: Regional Segmentation Analysis

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • The UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

KEY REPORT POINTERS & HIGHLIGHTS:

  • Statistically Validated Analysis of Historical, Current, and Projected Industry Trends with Authenticated Market Sizes Information and Data in terms of Value and Volume, wherever applicable
  • Direct and Indirect Factors that Impacted the Industry as well Projected Rationales expected to affect the industry going forward
  • Micro, Meso, Macro, and In-Depth Analysis of Technically relevant and Commercially viable  Segments and Sub-segments of the Market
  • Historical and Projected Company / Vendor / OEM / Supplier Market Shares, Competitive Landscape, and Player Positioning Data
  • Historical and Current Demand (Consumption) and Supply (Production) Scenarios as well as Projected Supply-Demand Scenario Analysis
  • Detailed List of Key Buyers and End-Users (Consumers) analyzed as per Regions and Applications
  • Value Chain and Supply Chain Analysis along with Horizontal and Vertical Integration Scenarios
  • Manufacturing and Production Cost Structure Analysis including Labor Cost, Raw Material Expenses, and Other Manufacturing Expenses, wherever relevant
  • Overview of Key Marketing Strategies and Key Sales Channels Adopted in the Market
  • Market Attractiveness Analysis and Key Investment Opportunity Analysis in the Market going forward
  • Technological Roadmap, Patents Analysis, Potential Substitutes, and Technical Analysis

The professionally substantiated market research report study is calculated, constructed, and assembled by implementing a Robust Research Methodology. The Triangular Process comprises a buoyant mix of Exhaustive Primary Research (focused interviews, questionnaires, and ad-hoc surveys) and Extended Secondary Research (paid external databases, proprietary in-house database, and publically-available validated sources), where it is finally triangulated and validated through in-house industry experts, industry leaders, and independent consultants through a tri-level quality check practice.

Table of Content

CHAPTER 1.... Executive Summary

CHAPTER 2.... Hemoglobinopathies market – Indication Analysis

2.1.        Global Hemoglobinopathies Market–IndicationOverview

2.2.        Global HemoglobinopathiesMarketShare, by Indication, 2018 & 2025 (USD Million)

2.3.        Sickle cell disease

2.3.1.     Global Sickle cell diseaseHemoglobinopathiesMarket,2016-2026 (USD Million)

2.4.        Alpha Thalassemia

2.4.1.     Global Alpha ThalassemiaHemoglobinopathiesMarket,2016-2026 (USD Million)

2.5.        Beta Thalassemia

2.5.1.     Global Beta ThalassemiaHemoglobinopathiesMarket,2016-2026 (USD Million)

2.6.        Others

2.6.1.     Global OthersHemoglobinopathiesMarket,2016-2026 (USD Million)

CHAPTER 3.... Hemoglobinopathies market – Therapy Analysis

3.1.        Global Hemoglobinopathies Market–TherapyOverview

3.2.        Global HemoglobinopathiesMarketShare, by Therapy, 2018 & 2025 (USD Million)

3.3.        Blood Transfusion

3.3.1.     Global Blood TransfusionHemoglobinopathiesMarket,2016-2026 (USD Million)

3.4.        Iron Chelation Therapy

3.4.1.     Global Iron Chelation TherapyHemoglobinopathiesMarket,2016-2026 (USD Million)

3.5.        Bone Marrow Transplant

3.5.1.     Global Bone Marrow TransplantHemoglobinopathiesMarket,2016-2026 (USD Million)

3.6.        Others

3.6.1.     Global OthersHemoglobinopathiesMarket,2016-2026 (USD Million)

CHAPTER 4.... Hemoglobinopathies market – Diagnosis Analysis

4.1.        Global Hemoglobinopathies Market–DiagnosisOverview

4.2.        Global HemoglobinopathiesMarketShare, by Diagnosis, 2018 & 2025 (USD Million)

4.3.        Blood Testing

4.3.1.     Global Blood TestingHemoglobinopathiesMarket,2016-2026 (USD Million)

4.4.        Genetic testing

4.4.1.     Global Genetic testingHemoglobinopathiesMarket,2016-2026 (USD Million)

4.5.        Pre-implantation Genetic Diagnosis (PGD)

4.5.1.     Global Pre-implantation Genetic Diagnosis (PGD)HemoglobinopathiesMarket,2016-2026 (USD Million)

4.6.        Other

4.6.1.     Global OtherHemoglobinopathiesMarket,2016-2026 (USD Million)

CHAPTER 5.... Hemoglobinopathies market – End-user Analysis

5.1.        Global Hemoglobinopathies Market–End-userOverview

5.2.        Global HemoglobinopathiesMarketShare, by End-user, 2018 & 2025 (USD Million)

5.3.        Hospitals

5.3.1.     Global HospitalsHemoglobinopathiesMarket,2016-2026 (USD Million)

5.4.        Diagnostic laboratories

5.4.1.     Global Diagnostic laboratoriesHemoglobinopathiesMarket,2016-2026 (USD Million)

5.5.        Clinics

5.5.1.     Global ClinicsHemoglobinopathiesMarket,2016-2026 (USD Million)

5.6.        Other End-use

5.6.1.     Global Other End-useHemoglobinopathiesMarket,2016-2026 (USD Million)

CHAPTER 6.... Hemoglobinopathies market – Regional Analysis

6.1.        Global Hemoglobinopathies MarketRegionalOverview

6.2.        Global HemoglobinopathiesMarketShare, by Region, 2018 & 2025 (Value)

6.3.        North America

6.3.1.     North AmericaHemoglobinopathies Market size and forecast, 2016-2026

6.3.2.     North AmericaHemoglobinopathies Market, by Country, 2018 & 2025 (USD Million)

6.3.3.     North AmericaHemoglobinopathies Market, by Indication, 2016-2026

6.3.4.     North AmericaHemoglobinopathies Market, by Therapy, 2016-2026

6.3.5.     North AmericaHemoglobinopathies Market, by Diagnosis, 2016-2026

6.3.6.     North AmericaHemoglobinopathies Market, by End-user, 2016-2026

6.3.7.     U.S.

6.3.8.     Canada

6.4.        Europe

6.4.1.     EuropeHemoglobinopathies Market size and forecast, 2016-2026

6.4.2.     EuropeHemoglobinopathies Market, by Country, 2018 & 2025 (USD Million)

6.4.3.     EuropeHemoglobinopathies Market, by Indication, 2016-2026

6.4.4.     EuropeHemoglobinopathies Market, by Therapy, 2016-2026

6.4.5.     EuropeHemoglobinopathies Market, by Diagnosis, 2016-2026

6.4.6.     EuropeHemoglobinopathies Market, by End-user, 2016-2026

6.4.7.     Germany

6.4.8.     France

6.4.9.     U.K.

6.4.10.  Italy

6.4.11.  Spain

6.4.12.  Rest of Europe

6.5.        Asia Pacific

6.5.1.     Asia PacificHemoglobinopathies Market size and forecast, 2016-2026

6.5.2.     Asia PacificHemoglobinopathies Market, by Country, 2018 & 2025 (USD Million)

6.5.3.     Asia PacificHemoglobinopathies Market, by Indication, 2016-2026

6.5.4.     Asia PacificHemoglobinopathies Market, by Therapy, 2016-2026

6.5.5.     Asia PacificHemoglobinopathies Market, by Diagnosis, 2016-2026

6.5.6.     Asia PacificHemoglobinopathies Market, by End-user, 2016-2026

6.5.7.     China

6.5.8.     Japan

6.5.9.     India

6.5.10.  South  Korea

6.5.11.  South-East Asia

6.5.12.  Rest of Asia Pacific

6.6.        Latin America

6.6.1.     Latin AmericaHemoglobinopathies Market size and forecast, 2016-2026

6.6.2.     Latin AmericaHemoglobinopathies Market, by Country, 2018 & 2025 (USD Million)

6.6.3.     Latin AmericaHemoglobinopathies Market, by Indication, 2016-2026

6.6.4.     Latin AmericaHemoglobinopathies Market, by Therapy, 2016-2026

6.6.5.     Latin AmericaHemoglobinopathies Market, by Diagnosis, 2016-2026

6.6.6.     Latin AmericaHemoglobinopathies Market, by End-user, 2016-2026

6.6.7.     Brazil

6.6.8.     Mexico

6.6.9.     Rest of Latin America

6.7.        The Middle-East and Africa

6.7.1.     The Middle-East and AfricaHemoglobinopathies Market size and forecast, 2016-2026

6.7.2.     The Middle-East and AfricaHemoglobinopathies Market, by Country, 2018 & 2025 (USD Million)

6.7.3.     The Middle-East and AfricaHemoglobinopathies Market, by Indication, 2016-2026

6.7.4.     The Middle-East and AfricaHemoglobinopathies Market, by Therapy, 2016-2026

6.7.5.     The Middle-East and AfricaHemoglobinopathies Market, by Diagnosis, 2016-2026

6.7.6.     The Middle-East and AfricaHemoglobinopathies Market, by End-user, 2016-2026

6.7.7.     GCC Countries

6.7.8.     South Africa

6.7.9.     Rest of Middle-East Africa

CHAPTER 7.... Hemoglobinopathies market – Competitive Landscape

7.1.        Competitor Market Share – Revenue

7.2.        Market Concentration Rate Analysis, Top 3 and Top 5 Players

7.3.        Strategic Development

7.3.1.     Acquisitions and Mergers

7.3.2.     New Products

7.3.3.     Research & Development Activities

CHAPTER 8.... Company Profiles

8.1.        Alnylam Pharmaceuticals

8.1.1.     Company Overview

8.1.2.     Alnylam PharmaceuticalsRevenue and Gross Margin

8.1.3.     Product portfolio

8.1.4.     Recent initiatives

8.2.        Bluebird bio Inc.

8.2.1.     Company Overview

8.2.2.     Bluebird bio Inc.Revenue and Gross Margin

8.2.3.     Product portfolio

8.2.4.     Recent initiatives

8.3.        Celgene Corporation

8.3.1.     Company Overview

8.3.2.     Celgene CorporationRevenue and Gross Margin

8.3.3.     Product portfolio

8.3.4.     Recent initiatives

8.4.        Emmaus Life Sciences Inc.

8.4.1.     Company Overview

8.4.2.     Emmaus Life Sciences Inc.Revenue and Gross Margin

8.4.3.     Product portfolio

8.4.4.     Recent initiatives

8.5.        Gamida Cell

8.5.1.     Company Overview

8.5.2.     Gamida CellRevenue and Gross Margin

8.5.3.     Product portfolio

8.5.4.     Recent initiatives

8.6.        Global Blood Therapeutics

8.6.1.     Company Overview

8.6.2.     Global Blood TherapeuticsRevenue and Gross Margin

8.6.3.     Product portfolio

8.6.4.     Recent initiatives

8.7.        Prolong Pharmaceuticals

8.7.1.     Company Overview

8.7.2.     Prolong PharmaceuticalsRevenue and Gross Margin

8.7.3.     Product portfolio

8.7.4.     Recent initiatives

8.8.        Sangamo Therapeutics Inc.

8.8.1.     Company Overview

8.8.2.     Sangamo Therapeutics Inc.Revenue and Gross Margin

8.8.3.     Product portfolio

8.8.4.     Recent initiatives

8.9.        Sanofi

8.9.1.     Company Overview

8.9.2.     SanofiRevenue and Gross Margin

8.9.3.     Product portfolio

8.9.4.     Recent initiatives

CHAPTER 9.... Hemoglobinopathies — Industry Analysis

9.1.        Hemoglobinopathies Market – Key Trends

9.1.1.     Market Drivers

9.1.2.     Market Restraints

9.1.3.     Market Opportunities

9.2.        Value Chain Analysis

9.3.        Technology Roadmap and Timeline

9.4.        Hemoglobinopathies Market – Attractiveness Analysis

9.4.1.     By Indication

9.4.2.     By Therapy

9.4.3.     By Diagnosis

9.4.4.     By End-user

9.4.5.     By Region

CHAPTER 10. Marketing Strategy Analysis, Distributors

10.1.      Marketing Channel

10.2.      Direct Marketing

10.3.      Indirect Marketing

10.4.      Marketing Channel Development Trend

10.5.      Economic/Political Environmental Change

CHAPTER 11. Report Conclusion

CHAPTER 12. Research Approach & Methodology

12.1.      Report Description

12.2.      Research Scope

12.3.      Research Methodology

12.3.1.  Secondary Research

12.3.2.  Primary Research

12.3.3.  Models


List of Figures

FIG. 1. Global Hemoglobinopathies Market, 2016-2026(USD Million)

FIG. 2. Global Hemoglobinopathies MarketShare, by Indication, 2018 & 2025 (USD Million)

FIG. 3. Global Sickle cell diseaseHemoglobinopathiesMarket,2016-2026 (USD Million)

FIG. 4. Global Alpha ThalassemiaHemoglobinopathiesMarket,2016-2026 (USD Million)

FIG. 5. Global Beta ThalassemiaHemoglobinopathiesMarket,2016-2026 (USD Million)

FIG. 6. Global OthersHemoglobinopathiesMarket,2016-2026 (USD Million)

FIG. 7. Global Hemoglobinopathies MarketShare, by Therapy, 2018 & 2025 (USD Million)

FIG. 8. Global Blood TransfusionHemoglobinopathiesMarket,2016-2026 (USD Million)

FIG. 9. Global Iron Chelation TherapyHemoglobinopathiesMarket,2016-2026 (USD Million)

FIG. 10. Global Bone Marrow TransplantHemoglobinopathiesMarket,2016-2026 (USD Million)

FIG. 11. Global OthersHemoglobinopathiesMarket,2016-2026 (USD Million)

FIG. 12. Global Hemoglobinopathies MarketShare, by Diagnosis, 2018 & 2025 (USD Million)

FIG. 13. Global Blood TestingHemoglobinopathiesMarket,2016-2026 (USD Million)

FIG. 14. Global Genetic testingHemoglobinopathiesMarket,2016-2026 (USD Million)

FIG. 15. Global Pre-implantation Genetic Diagnosis (PGD)HemoglobinopathiesMarket,2016-2026 (USD Million)

FIG. 16. Global OtherHemoglobinopathiesMarket,2016-2026 (USD Million)

FIG. 17. Global Hemoglobinopathies MarketShare, by End-user, 2018 & 2025 (USD Million)

FIG. 18. Global HospitalsHemoglobinopathiesMarket,2016-2026 (USD Million)

FIG. 19. Global Diagnostic laboratoriesHemoglobinopathiesMarket,2016-2026 (USD Million)

FIG. 20. Global ClinicsHemoglobinopathiesMarket,2016-2026 (USD Million)

FIG. 21. Global Other End-useHemoglobinopathiesMarket,2016-2026 (USD Million)

FIG. 22. Global Hemoglobinopathies MarketShare, by Region, 2018 & 2025

FIG. 23. North AmericaHemoglobinopathies Market, 2016-2026

FIG. 24. U.S.Hemoglobinopathies Market, 2016-2026

FIG. 25. CanadaHemoglobinopathies Market, 2016-2026

FIG. 26. EuropeHemoglobinopathies Market, 2016-2026

FIG. 27. GermanyHemoglobinopathies Market, 2016-2026

FIG. 28. FranceHemoglobinopathies Market, 2016-2026

FIG. 29. U.K.Hemoglobinopathies Market, 2016-2026

FIG. 30. ItalyHemoglobinopathies Market, 2016-2026

FIG. 31. SpainHemoglobinopathies Market, 2016-2026

FIG. 32. Rest of EuropeHemoglobinopathies Market, 2016-2026

FIG. 33. Asia PacificHemoglobinopathies Market, 2016-2026

FIG. 34. ChinaHemoglobinopathies Market, 2016-2026

FIG. 35. JapanHemoglobinopathies Market, 2016-2026

FIG. 36. IndiaHemoglobinopathies Market, 2016-2026

FIG. 37. South  KoreaHemoglobinopathies Market, 2016-2026

FIG. 38. South-East AsiaHemoglobinopathies Market, 2016-2026

FIG. 39. Rest of Asia PacificHemoglobinopathies Market, 2016-2026

FIG. 40. Latin AmericaHemoglobinopathies Market, 2016-2026

FIG. 41. BrazilHemoglobinopathies Market, 2016-2026

FIG. 42. MexicoHemoglobinopathies Market, 2016-2026

FIG. 43. Rest of Latin AmericaHemoglobinopathies Market, 2016-2026

FIG. 44. The Middle-East and AfricaHemoglobinopathies Market, 2016-2026

FIG. 45. GCC CountriesHemoglobinopathies Market, 2016-2026

FIG. 46. South AfricaHemoglobinopathies Market, 2016-2026

FIG. 47. Rest of Middle-East AfricaHemoglobinopathies Market, 2016-2026

FIG. 48. Competitor Market Share – Revenue

FIG. 49. Alnylam Pharmaceuticals Revenue and Growth Rate

FIG. 50. Alnylam Pharmaceuticals Market Share

FIG. 51. Bluebird bio Inc. Revenue and Growth Rate

FIG. 52. Bluebird bio Inc. Market Share

FIG. 53. Celgene Corporation Revenue and Growth Rate

FIG. 54. Celgene Corporation Market Share

FIG. 55. Emmaus Life Sciences Inc. Revenue and Growth Rate

FIG. 56. Emmaus Life Sciences Inc. Market Share

FIG. 57. Gamida Cell Revenue and Growth Rate

FIG. 58. Gamida Cell Market Share

FIG. 59. Global Blood Therapeutics Revenue and Growth Rate

FIG. 60. Global Blood Therapeutics Market Share

FIG. 61. Prolong Pharmaceuticals Revenue and Growth Rate

FIG. 62. Prolong Pharmaceuticals Market Share

FIG. 63. Sangamo Therapeutics Inc. Revenue and Growth Rate

FIG. 64. Sangamo Therapeutics Inc. Market Share

FIG. 65. Sanofi Revenue and Growth Rate

FIG. 66. Sanofi Market Share

FIG. 67. Market Dynamics

FIG. 68. Global Hemoglobinopathies – Value Chain Analysis

FIG. 69. Technology Roadmap and Timeline

FIG. 70. Market Attractiveness Analysis – By Indication

FIG. 71. Market Attractiveness Analysis – By Therapy

FIG. 72. Market Attractiveness Analysis – By Diagnosis

FIG. 73. Market Attractiveness Analysis – By End-user

FIG. 74. Market Attractiveness Analysis – By Region

FIG. 75. Market Channel

FIG. 76. Marketing Channel Development Trend

FIG. 77  Growth in World Gross Product, 2008-2018


List of Tables

TABLE 1    Global Hemoglobinopathies Market, 2018& 2025 (USD Million)
TABLE 2    Global Hemoglobinopathies market, by Indication, 2016-2026 (USD Million)
TABLE 3    Global Hemoglobinopathies market, by Therapy, 2016-2026 (USD Million)
TABLE 4    Global Hemoglobinopathies market, by Diagnosis, 2016-2026 (USD Million)
TABLE 5    Global Hemoglobinopathies market, by End-user, 2016-2026 (USD Million)
TABLE 6    Global Hemoglobinopathies market, by Region, 2016-2026 (USD Million)
TABLE 7    North AmericaHemoglobinopathies Market, by Indication, 2016-2026 (USD Million)
TABLE 8    North AmericaHemoglobinopathies Market, by Therapy, 2016-2026 (USD Million)
TABLE 9    North AmericaHemoglobinopathies Market, by Diagnosis, 2016-2026 (USD Million)
TABLE 10    North AmericaHemoglobinopathies Market, by End-user, 2016-2026 (USD Million)
TABLE 11    EuropeHemoglobinopathies Market, by Indication, 2016-2026 (USD Million)
TABLE 12    EuropeHemoglobinopathies Market, by Therapy, 2016-2026 (USD Million)
TABLE 13    EuropeHemoglobinopathies Market, by Diagnosis, 2016-2026 (USD Million)
TABLE 14    EuropeHemoglobinopathies Market, by End-user, 2016-2026 (USD Million)
TABLE 15    Asia PacificHemoglobinopathies Market, by Indication, 2016-2026 (USD Million)
TABLE 16    Asia PacificHemoglobinopathies Market, by Therapy, 2016-2026 (USD Million)
TABLE 17    Asia PacificHemoglobinopathies Market, by Diagnosis, 2016-2026 (USD Million)
TABLE 18    Asia PacificHemoglobinopathies Market, by End-user, 2016-2026 (USD Million)
TABLE 19    Latin AmericaHemoglobinopathies Market, by Indication, 2016-2026 (USD Million)
TABLE 20    Latin AmericaHemoglobinopathies Market, by Therapy, 2016-2026 (USD Million)
TABLE 21    Latin AmericaHemoglobinopathies Market, by Diagnosis, 2016-2026 (USD Million)
TABLE 22    Latin AmericaHemoglobinopathies Market, by End-user, 2016-2026 (USD Million)
TABLE 23    The Middle-East and AfricaHemoglobinopathies Market, by Indication, 2016-2026 (USD Million)
TABLE 24    The Middle-East and AfricaHemoglobinopathies Market, by Therapy, 2016-2026 (USD Million)
TABLE 25    The Middle-East and AfricaHemoglobinopathies Market, by Diagnosis, 2016-2026 (USD Million)
TABLE 26    The Middle-East and AfricaHemoglobinopathies Market, by End-user, 2016-2026 (USD Million)
TABLE 27    Global Hemoglobinopathies Market - Company Revenue Analysis 2016-2019 (USD Million)
TABLE 28    Global Hemoglobinopathies Market - Company Revenue Share Analysis 2016-2019(%)
TABLE 29    Acquisitions and Mergers
TABLE 30    New Product/Service Launch
TABLE 31    Research & Development Activities
TABLE 32    Market Drivers
TABLE 33    Market Restraints
TABLE 34    Market Opportunities

Key Insights from Primary Research

  • According to the primary CXO’s of the global hemoglobinopathies market, the market is estimated to witness a substantial growth of nearly 13.42% over the forecast period.
  • The market was valued at USD 5,423.5 million, in 2019 and is expected to be valued over USD 13,465.2 million.
  • On the basis of the therapy segment, blood transfusion therapy held the largest market share. Rising policy measures to increase the number of blood donors are a high impact making engine for the demand for hemoglobinopathies.
  • Geography-wise, the Asia Pacific market is likely to be the fastest-growing region for hemoglobinopathies over the forecast period.
  • By geography, the North America region headed the market with a share of above 32.5%, in 2019.

Key Recommendations from Analysts

  • Improved R&D investments are projected to contribute to demand development for new therapies. The National Heart, Lung, and Blood Institute (NHLBI), part of the National Health Institutes (NIH), is funding SCD research programs to find new methods of identifying and managing the disease and enhancing patient outcomes.
  • The strategic developments such as regional expansion, product innovations and on-going research and developments by the major companies such as CytoTherm Alnylam Pharmaceuticals, bluebird bio Inc., Celgene Corporation is likely to boom the market’s growth over the upcoming years.
  • Our analysts advise that the Asia Pacific region will probably witness a significant growth attributed to the growing demand for hemoglobinopathies from the developing countries like India.     
  • Expansion of manufacturing plants or distribution channels of pharmaceuticals companies especially in the emerging market is predicted to fuel the demand for hemoglobinopathies drug in the developing economies over the forecast years.

Industry Major Market Players

  • Alnylam Pharmaceuticals
  •  bluebird bio Inc.
  •  Celgene Corporation
  •  Emmaus Life Sciences Inc.
  •  Gamida Cell
  •  Global Blood Therapeutics
  •  Prolong Pharmaceuticals
  •  Sangamo
  •  Therapeutics Inc.
  •  Sanofi

Safe and Secure SSL Encrypted

Choose License Type

Inquiry For Buying

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

have a question

HAVE A QUESTION? Executive will help you find what you are looking for.


REQUEST CUSTOMIZATION

Still haven't found what you're looking for? Speak to our Custom Research Team

Learn More
Facts & Factors provides an array of marketing and business research solutions distinctly designed by our expertise for the clients.
Copyright © 2020 Facts & Factors. All Rights Reserved. Sitemap - Privacy Policy - Terms & Conditions